The Pharma Data

DECEMBER 17, 2020

17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. patients under an Emergency Use Authorization, and we also continue a robust clinical development program.” TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

JANUARY 12, 2021

Regeneron Pharmaceuticals, Inc. Nursing Mothers: There is currently no clinical experience in use of casirivimab and imdevimab injection in COVID-19 patients who are breastfeeding. NASDAQ: REGN ) today announced that the U.S. Forward-Looking Statements and Use of Digital Media.

Government 52

Government Hospitals Virus Production 52

The Pharma Data

DECEMBER 29, 2020

Regeneron Pharmaceuticals, Inc. Nursing Mothers: There is currently no clinical experience in use of casirivimab and imdevimab injection in COVID-19 patients who are breastfeeding. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

NOVEMBER 20, 2020

November 21, 2020 – Regeneron Pharmaceuticals, Inc. Food and Drug Administration (FDA). Nursing Mothers: There is currently no clinical experience in use of casirivimab and imdevimab injection in COVID-19 patients who are breastfeeding. TARRYTOWN, N.Y., About Regeneron.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 21, 2020

Regeneron Pharmaceuticals, Inc. Nursing Mothers: There is currently no clinical experience in use of casirivimab and imdevimab injection in COVID-19 patients who are breastfeeding. Initial doses of REGEN-COV2 will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S.

FDA 40

FDA Clinical Trials Hospitals Government 40